Clinical results with Taleum in the treatment of extrinsic bronchial asthma.
Taleum inhalation aerosol, produced by EGIS Pharmaceuticals Works, was examined in an 8-week open cross-over self-controlled study in 50 patients suffering from extrinsic bronchial asthma. Intal powder capsule inhaled with the aid of a spinhaler was used as a reference drug. Changes in subjective complaints and symptoms were continuously recorded on a score scale in the patients' diary. The alterations in respiratory parameters were measured. Laboratory parameters were monitored. On the basis of the results Taleum spray was found to be effective in the prevention of bronchial asthma. It proved to be a well tolerated drug form of simple use.
Alexy
G
G
T. B. Clinic of Unified Health Institutions, Pécs, Hungary.
Sárdi
F
F
D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D000336:Aerosols; D000403:Airway Resistance / Q000187:drug effects; D001249:Asthma / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D004205:Cromolyn Sodium / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D006967:Hypersensitivity / Q000150:complications*; D008297:Male; D010366:Peak Expiratory Flow Rate / Q000187:drug effects; D014797:Vital Capacity / Q000187:drug effects
D000336:Aerosols; D004205:Cromolyn Sodium